AUTHOR=Mele Marco , Imbrici Paola , Mele Antonietta , Togo Maria Vittoria , Dinoi Giorgia , Correale Michele , Brunetti Natale Daniele , Nicolotti Orazio , De Luca Annamaria , Altomare Cosimo Damiano , Liantonio Antonella , Amoroso Nicola TITLE=Short-term anti-remodeling effects of gliflozins in diabetic patients with heart failure and reduced ejection fraction: an explainable artificial intelligence approach JOURNAL=Frontiers in Pharmacology VOLUME=Volume 14 - 2023 YEAR=2023 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1175606 DOI=10.3389/fphar.2023.1175606 ISSN=1663-9812 ABSTRACT=Sodium-glucose cotransporter type 2 inhibitors (SGLT2i), gliflozins, play an emerging role for the treatment of heart failure with reduced left ventricular ejection fraction (HFrEF). Nevertheless, the effects of SGLT2i on ventricular remodeling and function have not been completely understood yet. Explainable artificial intelligence (XAI) represents an unprecedented explorative option to clinical research in this field. Based on echocardiographic evaluations, we identified some key clinical responses to gliflozins by employing a machine learning (ML) approach. Seventy-eight consecutive diabetic outpatients followed for HFrEF were enrolled in the study. Using a Random Forests classification, a single subject analysis was performed to define the profile of patients treated with gliflozins. An eXplainability analysis using Shapley values was used to outline clinical parameters that mostly improved after gliflozin therapy and machine learning runs highlighted specific variables predictive of gliflozin response. The 5-fold cross-validation analyses showed that gliflozins patients can be identified with a 0.70±0.03% accuracy. The most relevant parameters distinguishing gliflozins patients were Right Ventricular S’-Velocity, Left Ventricular End Systolic Diameter (LVESD) and E/e’ ratio. In addition, low Tricuspid Annular Plane Systolic Excursion values along with high LVESD and End Diastolic Volume values were associated to lower gliflozin efficacy in terms of anti-remodeling effects. In conclusion, a ML analysis on a population of diabetic patients with HFrEF showed that SGLT2i treatment improved LV remodeling, LV diastolic and biventricular systolic function. This cardiovascular response may be predicted by routine echocardiographic parameters, with an XAI approach, suggesting a lower efficacy in case of advanced stages of cardiac remodeling.